Filing Flows › TScan Therapeutics (TCRX) › Q2 2026
TScan Therapeutics (TCRX) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 12, 2026
TScan Therapeutics (TCRX) reported revenue of $1.1M for the second quarter 2026 (Q2 2026), -66% from a year earlier and +7% from the quarter before.
TScan Therapeutics, Q2 2026: revenue $1.1M (-66% year over year), net loss $30.4M, operating cash flow −$27.5M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.1M | +7% | -66% |
| Operating profit | −$30.5M | — | — |
| Net earnings | −$30.4M | — | — |
| Operating cash flow | −$27.5M | — | — |
What changed
Revenue was $1.1M in Q2 2026, down 66% year over year and up 7% from the previous quarter.
Operating costs exceeded revenue by $30.5M, an operating margin of -2901.3%. Total costs fell 24% while revenue fell 66%. The quarter ended with a net loss of $30.4M, wider than the previous quarter's $28.7M loss.
Operating cash flow was −$27.5M. Non-cash charges added back $699K of depreciation and $2.4M of share-based compensation. Capital expenditures of $493K exceeded it, leaving free cash flow of −$28.0M.
Questions
What was TScan Therapeutics' revenue in the second quarter 2026?
TScan Therapeutics (TCRX) reported revenue of $1.1M for the second quarter 2026 (Q2 2026), -66% from a year earlier and +7% from the quarter before.
Source: TScan Therapeutics 10-Q on SEC EDGAR.